Status:
COMPLETED
In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
Lead Sponsor:
University of Pittsburgh
Conditions:
Cutaneous T-cell Lymphoma
Sezary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.
Detailed Description
This is an in vitro evaluation of cutaneous T-cell lymphoma using patients blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/ CD 8 cells with the foll...
Eligibility Criteria
Inclusion
- Males or females \<18 years of age
- Histologically confirmed stage IV cutaneous T-cell lymphoma, with at least 5% of the peripheral blood lymphocytes showing atypical morphology consistent with Sezary cells
- Ambulatory and be in stable medical condition
- Biopsy positive mycosis fungoides/CTCL or clonal type of CTCL as determined by PCR for TCR and Southern blot for TCR
Exclusion
- Received any chemotherapy or radiotherapy within 4 weeks prior to enrollment
- Significant psychiatric illness which would prevent adequate informed consent in the opinion of the principal investigator
- Systemic steroid therapy other than maintenance for adrenal suppression
- Known coagulopathy for non SS subjects.
Key Trial Info
Start Date :
June 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00177190
Start Date
June 1 2002
End Date
January 1 2006
Last Update
May 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213